Atecegatran metoxil
| Code | Size | Price |
|---|
| TAR-T30192-5mg | 5mg | £1,010.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T30192-50mg | 50mg | £1,982.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T30192-100mg | 100mg | £2,560.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Atecegatran Metoxil (Atecegatran Fexenetil ,AZD0837) is an oral direct thrombin inhibitor,which currently in clinical development for the prevention of stroke and systemic embolic events in patients with atrial fibrillation. AZD0837 is a selective and reversible direct thrombin inhibitor and is a bioconverted to AR-H067637.AZD0837 is well tolerated in healthy male subjects at a single oral dose (15-750 mg) and demonstrated favorable PK properties and reproducible effects on in vitro coagulation time variables, supporting further clinical development.
CAS:
433937-93-0
Formula:
C22H23ClF2N4O5
Molecular Weight:
496.9
Purity:
0.98
SMILES:
CONC(=N)c1ccc(CNC(=O)[C@@H]2CCN2C(=O)[C@H](O)c2cc(Cl)cc(OC(F)F)c2)cc1
References
1. Lip GY, Rasmussen LH, Olsson SB, Jensen E, Hamr?n B, Eriksson UG, W?hlander K. Exposure-response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation. Br J Clin Pharmacol. 2015 Dec;80(6):1362-73. doi: 10.1111/bcp.12719. Epub 2015 Sep 22. PubMed PMID: 26174611.
2. Dun?r K, Hulthe J, Tranberg M. Determination of the thrombin inhibitor AZD0837 and its metabolites in human bile using mixed mode solid phase extraction and LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Sep 1;904:29-34. doi: 10.1016/j.jchromb.2012.06.026. Epub 2012 Jun 28. PubMed PMID: 22871267.
3. Wolzt M, Eriksson UG, Gouya G, Leuchten N, Kapiotis S, Elg M, Sch?tzer KM, Zetterstrand S, Holmberg M, W?hlander K. Effect on perfusion chamber thrombus size in patients with atrial fibrillation during anticoagulant treatment with oral direct thrombin inhibitors, AZD0837 or ximelagatran, or with vitamin K antagonists. Thromb Res. 2012 Apr;129(4):e83-91. doi: 10.1016/j.thromres.2011.08.018. Epub 2011 Sep 16. PubMed PMID: 21925716.
4. Johansson S, Cullberg M, Eriksson UG, Elg M, Dun?r K, Jensen E, Wollbratt M, W?hlander K. Single-dose pharmacokinetics, pharmacodynamics and safety of AZD0837, a novel oral direct thrombin inhibitor, in young healthy male subjects. Int J Clin Pharmacol Ther. 2011 Apr;49(4):258-67. doi: 10.5414/CP201465. PubMed PMID: 21429440.